Studies evaluating the frequency of HIT between UFH and LMWH for which gender information was available
. | Frequency of HIT (%) . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Study (LMWH), by setting . | Female, UFH . | Male, UFH . | Female, LMWH . | Male, LMWH . | |||
| Surgery | |||||||
| RCT28 (enoxaparin) | 13 of 173 (7.5) | 3 of 159 (1.9) | 1 of 187 (0.5) | 1 of 146 (0.7) | |||
| PCS (B/A)29 (enoxaparin) | 10 of 131 (7.6) | 2 of 100 (2.0) | 0 of 171 (0.0) | 0 of 100 (0.0) | |||
| PCS (B/A)30 (enoxaparin) | 5 of 182 (2.7) | 0 of 70 (0.0) | 1 of 171 (0.6) | 0 of 81 (0.0) | |||
| PCS31 (dalteparin) | 4 of 55 (7.3) | 2 of 102 (2.0) | 0 of 39 (0.0) | 0 of 132 (0.0) | |||
| Medical | |||||||
| PCS (B/A)32 (nadroparin) | 4 of 93 (4.3) | 1 of 107 (0.9) | 0 of 75 (0.0) | 0 of 36 (0.0) | |||
| RCT33 (reviparin) | 1 of 169 (0.6) | 0 of 206 (0.0) | 0 of 347 (0.0) | 0 of 415 (0.0) | |||
| PCS34,35 (several*) | 4 of 332 (1.2) | 1 of 266 (0.4) | 5 of 830 (0.6) | 9 of 935 (1.0) | |||
. | Frequency of HIT (%) . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Study (LMWH), by setting . | Female, UFH . | Male, UFH . | Female, LMWH . | Male, LMWH . | |||
| Surgery | |||||||
| RCT28 (enoxaparin) | 13 of 173 (7.5) | 3 of 159 (1.9) | 1 of 187 (0.5) | 1 of 146 (0.7) | |||
| PCS (B/A)29 (enoxaparin) | 10 of 131 (7.6) | 2 of 100 (2.0) | 0 of 171 (0.0) | 0 of 100 (0.0) | |||
| PCS (B/A)30 (enoxaparin) | 5 of 182 (2.7) | 0 of 70 (0.0) | 1 of 171 (0.6) | 0 of 81 (0.0) | |||
| PCS31 (dalteparin) | 4 of 55 (7.3) | 2 of 102 (2.0) | 0 of 39 (0.0) | 0 of 132 (0.0) | |||
| Medical | |||||||
| PCS (B/A)32 (nadroparin) | 4 of 93 (4.3) | 1 of 107 (0.9) | 0 of 75 (0.0) | 0 of 36 (0.0) | |||
| RCT33 (reviparin) | 1 of 169 (0.6) | 0 of 206 (0.0) | 0 of 347 (0.0) | 0 of 415 (0.0) | |||
| PCS34,35 (several*) | 4 of 332 (1.2) | 1 of 266 (0.4) | 5 of 830 (0.6) | 9 of 935 (1.0) | |||
Frequency of HIT is defined as number of patients with HIT out of number of total patients exposed.
B/A indicates before and after; PCS, prospective cohort study.
LMWH preparations were nadroparin (n = 880 patients), enoxaparin (n = 700 patients), reviparin (n = 67 patients), dalteparin (n = 64 patients), and pamaparin (n = 43 patients).